A Phase I Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
Latest Information Update: 15 Mar 2023
At a glance
- Drugs Copper-gluconate/disulfiram (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms Repurpose-1
- 09 Mar 2023 Status changed from recruiting to discontinued.
- 24 May 2021 Status changed from not yet recruiting to recruiting.
- 12 Mar 2021 Planned initiation date changed from 1 Feb 2021 to 1 Apr 2021.